Literature DB >> 19828934

Development of the performance measure for activities of daily living-8 for patients with congestive heart failure: a preliminary study.

Yuko Shimizu1, Sumio Yamada, Makoto Suzuki, Hiroko Miyoshi, Yuji Kono, Hideo Izawa, Rinya Kato, Toyoaki Murohara.   

Abstract

BACKGROUND: Functional limitations often lead to hospitalization, disease progression, and mortality in patients with congestive heart failure (CHF). Functional limitations become a particular problem among older patients. Self-reported questionnaires have been found to be a reliable and accurate methodology for obtaining information on functional limitations. However, current measures have been criticized for their inability to guide therapy on the basis of outcome data and for the lack of specificity of questions related to disease-specific symptoms.
OBJECTIVE: To develop the Performance Measure for Activities of Daily Living-8 (PMADL-8) to assess functional limitations in CHF patients and to provide preliminary data on internal consistency of the PMADL-8, as well as its reliability and validity.
METHODS: Using the International Classification of Functioning, Disability and Health model, functional limitation questionnaire items to assess difficulty in 8 common daily tasks in CHF patients were developed. The instrument was constructed based on input from a panel of experts and by pilot testing. Its construct and convergent validity, Rasch analysis, internal consistency, and test-retest reliability were evaluated in 50 CHF patients. Discriminative/known-group validity was investigated by comparing 37 elderly CHF patients and 37 age- and sex-matched controls from the general population.
RESULTS: Cronbach's alpha of the PMADL-8 was 0.94. The intraclass correlation coefficient was 0.96. The PMADL-8 was unidimensional and fitted the Rasch model. Expected differences in the PMADL-8 scores of known-groups show its discriminative/known-group validity. The PMADL-8 had good correlations with the dyspnea (r=0.77, p<0.01) and fatigue scores of the Marianna Heart Failure Questionnaire (r=0.69, p<0.01) and the New York Heart Association classification (F=26.7, p<0.01), demonstrating its convergent validity. Between 2 groups divided by the median scores of PMADL-8, there were significant differences in some disease-specific measures: grip strength, knee extensor muscle strength, and brain natriuretic peptide levels.
CONCLUSION: The PMADL-8 had good internal consistency and test-retest reliability, as well as discriminative and convergent validity in CHF patients. Therefore, the PMADL-8 has the potential to be used to assess disease-specific functional limitations in CHF patients. Copyright (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19828934     DOI: 10.1159/000248628

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  4 in total

1.  Clinical characteristics of heart failure associated with functional dependence at admission in hospitalized elderly.

Authors:  Sara de Oliveira Xavier; Renata Eloah de Lucena Ferretti-Rebustini
Journal:  Rev Lat Am Enfermagem       Date:  2019-04-29

2.  Prognostic score based on physical frailty in patients with heart failure: a multicenter prospective cohort study (FLAGSHIP).

Authors:  Sumio Yamada; Takuji Adachi; Hideo Izawa; Toyoaki Murohara; Takaaki Kondo
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-09-30       Impact factor: 12.910

3.  Impact of weight loss in patients with heart failure with preserved ejection fraction: results from the FLAGSHIP study.

Authors:  Kenta Kamisaka; Kuniyasu Kamiya; Kotaro Iwatsu; Naoki Iritani; Shota Imoto; Takuji Adachi; Yuki Iida; Sumio Yamada
Journal:  ESC Heart Fail       Date:  2021-10-02

4.  A multicenter prospective cohort study to develop frailty-based prognostic criteria in heart failure patients (FLAGSHIP): rationale and design.

Authors:  Sumio Yamada; Takuji Adachi; Hideo Izawa; Toyoaki Murohara; Takaaki Kondo
Journal:  BMC Cardiovasc Disord       Date:  2018-08-02       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.